Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC
Novartis (NVS) reported the first interpretable results of evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to the best standard of care alone.
The good news is that the trial has met both primary endpoints of overall survival (OS) and radiographic progression-free survival (PFS). These results are expected to move 177Lu-PSMA-617 closer to becoming the targeted treatment for >80% of patients with advanced prostate cancer.
The safety profile was consistent with data reported in previous clinical studies.
The results from the VISION trial will be presented at an upcoming medical meeting and included in US and EU regulatory submissions.